July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Dehydrated Extracellular Membranes in the Treatment of Severe Dry Eye
Author Affiliations & Notes
  • Ankur A Parikh
    Northeast Ohio Medical University, Akron, Ohio, United States
  • Siri Yalamanchili
    Northeast Ohio Medical University, Akron, Ohio, United States
  • David Gemmel
    Mercy Health - St. Elizabeth Youngstown Hospital, Youngstown, Ohio, United States
  • Sergul Erzurum
    Northeast Ohio Medical University, Akron, Ohio, United States
    Eye Care Associates, Youngstown, Ohio, United States
  • Footnotes
    Commercial Relationships   Ankur Parikh, None; Siri Yalamanchili, None; David Gemmel, None; Sergul Erzurum, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6754. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ankur A Parikh, Siri Yalamanchili, David Gemmel, Sergul Erzurum; Dehydrated Extracellular Membranes in the Treatment of Severe Dry Eye. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6754.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Dry eye can severely affect a patient’s quality of vision and life. Common symptoms include redness, burning, and blurred vision. Even with multiple treatment options, some patients have persistent difficulty. In recent years, amniotic membranes have become a treatment option for a variety of ocular surface disorders including corneal ulcers, neurotrophic keratopathy, and chemical injury. The objective of this study is to evaluate the efficacy of dehydrated amniotic membrane (BioDOptix) use in patients with dry eye.

Methods : A retrospective chart review of patients receiving dehydrated amniotic membranes for severe dry eye in the past two years was conducted. Patients with other complicating eye diagnoses were excluded. Data on visual acuity, symptoms, and slit lamp examination (SLE) findings were collected prior to lens placement, 1-week, and 1-month after removal. A symptom count checklist of 14 items was summed to create an index, ranging from 0-14. A paired t-test was used to assess significant change at each interval.

Results : Chart audit yielded 28 eyes in 20 patients with an average patient age of 68+16 years. Prior to membrane treatment, therapies included natural tears (21/28), punctal plugs (18/28), Restasis®(13/28), Xiidra®(7/28), serum tears (4/28), and others (12/28).

At baseline, symptom count index was 1.4+1.0. Symptoms were 0.9+1.0 (t test = 2.478, p = 0.02) at one week and 0.6+1.0 at one month (t = 2.087, p = 0.054), demonstrating significant sustained reduction from baseline. Punctate epithelial erosions (PEE), measured on a scale of 0 – 4, were 2.8 +1.1 at baseline (n = 27). PEEs improved to 0.7 +0.8 at one week (t = 7.39, p < 0.001) and were sustained at one month, 0.6 +0.8 (t = 6.816, p < 0.001). LogMAR <0.1 visual acuity was 21% (6/28) at baseline. At 1 week, LogMAR <0.1 was similar to baseline, 22% (6/27). By 1-month, logMAR <0.1 increased to 50% (8/16); however, visual acuity was not statistically significant.

Conclusions : BioDOptix membranes have the advantage of being easily applied in an outpatient setting and patients find these lenses comfortable and easy to leave in place. BioDOptix membranes showed a significant rapid reduction in both symptoms and PEEs as well as an improvement in visual acuity. Thus, dehydrated amniotic membranes should be considered in the armamentarium to manage patients with difficult dry eye.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.